Candidiasis Therapeutics Market Growth Trajectory Through 2024-2033

The Candidiasis Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Candidiasis Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

According to The Business Research Company’s Candidiasis Therapeutics Global Market Report 2024, The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in 2023 to $3.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs..

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance.. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives..

The growing incidence of fungal infections is expected to propel the growth of the candidiasis therapeutics market going forward. Fungal infections are illnesses caused by various fungi that can affect the skin, mucous membranes, and internal organs in humans. The rising number of individuals with compromised immune systems and individuals with fungal infections increases the susceptibility to candidiasis, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs that target the underlying fungal pathogens, relieve symptoms, prevent complications, promote patient recovery, reduce the spread of Candida infections within healthcare facilities, and contribute to better patient outcomes. For instance, in July 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, fungal infection-related hospitalizations reached a total of 59,212 by 2021, with the rate of these hospitalizations increasing from 25.0 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, with an average annual increase of 8.5%. Moreover, the fungal hospitalizations with the highest death rates among COVID-19 patients were linked to aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%), and unspecified mycoses (59.0%). Therefore, the growing incidence of fungal infections will drive the growth of the candidiasis therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

The candidiasis therapeutics market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode of Administration: Injectable, Oral, Other Mode of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Major companies operating in the candidiasis therapeutics market are developing innovative drugs such as BREXAFEMME (ibrexafungerp tablets) to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) is an oral, non-azole medication for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a US-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. BREXAFEMME works by blocking the growth of Candida albicans, the fungus that causes VVC. Moreover, it is a safe and effective treatment option for vulvovaginal candidiasis (VVC). It is also available only by prescription, with a recommended dose of one 150-mg capsule taken orally once daily for one day.

The candidiasis therapeutics market report table of contents includes:

1. Executive Summary
2.Candidiasis Therapeutics Market Characteristics
3.Candidiasis Therapeutics Market Trends And Strategies
4.Candidiasis Therapeutics Market analysis
5.Candidiasis Therapeutics Market Size And Growth
6.Candidiasis Therapeutics Segmentation
7.Candidiasis Therapeutics Regional And Country Analysis
.
.
.
27.Candidiasis Therapeutics Competitive Landscape And Company Profiles
28.Candidiasis Therapeutics Key Mergers And Acquisitions
29.Candidiasis Therapeutics Future Outlook and Potential Analysis

TOP MAJOR PLAYERS: